These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32835256)

  • 21. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
    Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
    Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study.
    Sánchez-Guijo F; García-Arranz M; López-Parra M; Monedero P; Mata-Martínez C; Santos A; Sagredo V; Álvarez-Avello JM; Guerrero JE; Pérez-Calvo C; Sánchez-Hernández MV; Del-Pozo JL; Andreu EJ; Fernández-Santos ME; Soria-Juan B; Hernández-Blasco LM; Andreu E; Sempere JM; Zapata AG; Moraleda JM; Soria B; Fernández-Avilés F; García-Olmo D; Prósper F
    EClinicalMedicine; 2020 Aug; 25():100454. PubMed ID: 32838232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy.
    Nair JR; Edwards SW; Moots RJ
    Expert Opin Biol Ther; 2012 Dec; 12(12):1661-8. PubMed ID: 23094973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.
    Grasselli G; Greco M; Zanella A; Albano G; Antonelli M; Bellani G; Bonanomi E; Cabrini L; Carlesso E; Castelli G; Cattaneo S; Cereda D; Colombo S; Coluccello A; Crescini G; Forastieri Molinari A; Foti G; Fumagalli R; Iotti GA; Langer T; Latronico N; Lorini FL; Mojoli F; Natalini G; Pessina CM; Ranieri VM; Rech R; Scudeller L; Rosano A; Storti E; Thompson BT; Tirani M; Villani PG; Pesenti A; Cecconi M;
    JAMA Intern Med; 2020 Oct; 180(10):1345-1355. PubMed ID: 32667669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis.
    Di Franco M; Gerardi MC; Lucchino B; Conti F
    Core Evid; 2014; 9():41-8. PubMed ID: 24648832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
    Guaraldi G; Meschiari M; Cozzi-Lepri A; Milic J; Tonelli R; Menozzi M; Franceschini E; Cuomo G; Orlando G; Borghi V; Santoro A; Di Gaetano M; Puzzolante C; Carli F; Bedini A; Corradi L; Fantini R; Castaniere I; Tabbì L; Girardis M; Tedeschi S; Giannella M; Bartoletti M; Pascale R; Dolci G; Brugioni L; Pietrangelo A; Cossarizza A; Pea F; Clini E; Salvarani C; Massari M; Viale PL; Mussini C
    Lancet Rheumatol; 2020 Aug; 2(8):e474-e484. PubMed ID: 32835257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study.
    Martin-Loeches I; Povoa P; Rodríguez A; Curcio D; Suarez D; Mira JP; Cordero ML; Lepecq R; Girault C; Candeias C; Seguin P; Paulino C; Messika J; Castro AG; Valles J; Coelho L; Rabello L; Lisboa T; Collins D; Torres A; Salluh J; Nseir S;
    Lancet Respir Med; 2015 Nov; 3(11):859-68. PubMed ID: 26472037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia.
    Temesgen Z; Assi M; Vergidis P; Rizza SA; Bauer PR; Pickering BW; Razonable RR; Libertin CR; Burger CD; Orenstein R; Vargas HE; Varatharaj Palraj BR; Dababneh AS; Chappell G; Chappell D; Ahmed O; Sakemura R; Durrant C; Kenderian SS; Badley A
    medRxiv; 2020 Jun; ():. PubMed ID: 32587983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis.
    Crotti C; Biggioggero M; Becciolini A; Agape E; Favalli EG
    Expert Opin Investig Drugs; 2019 Jul; 28(7):573-581. PubMed ID: 31208237
    [No Abstract]   [Full Text] [Related]  

  • 32. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date.
    Crotti C; Raimondo MG; Becciolini A; Biggioggero M; Favalli EG
    Drug Des Devel Ther; 2017; 11():211-223. PubMed ID: 28144129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
    Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
    Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
    Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis.
    Wang B; Lau YY; Liang M; Vainshtein I; Zusmanovich M; Lu H; Magrini F; Sleeman M; Roskos L
    J Clin Pharmacol; 2012 Aug; 52(8):1150-61. PubMed ID: 21947370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anakinra for severe forms of COVID-19: a cohort study.
    Huet T; Beaussier H; Voisin O; Jouveshomme S; Dauriat G; Lazareth I; Sacco E; Naccache JM; Bézie Y; Laplanche S; Le Berre A; Le Pavec J; Salmeron S; Emmerich J; Mourad JJ; Chatellier G; Hayem G
    Lancet Rheumatol; 2020 Jul; 2(7):e393-e400. PubMed ID: 32835245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
    Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
    Richardson S; Hirsch JS; Narasimhan M; Crawford JM; McGinn T; Davidson KW; ; Barnaby DP; Becker LB; Chelico JD; Cohen SL; Cookingham J; Coppa K; Diefenbach MA; Dominello AJ; Duer-Hefele J; Falzon L; Gitlin J; Hajizadeh N; Harvin TG; Hirschwerk DA; Kim EJ; Kozel ZM; Marrast LM; Mogavero JN; Osorio GA; Qiu M; Zanos TP
    JAMA; 2020 May; 323(20):2052-2059. PubMed ID: 32320003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19.
    Strohbehn GW; Heiss BL; Rouhani SJ; Trujillo JA; Yu J; Kacew AJ; Higgs EF; Bloodworth JC; Cabanov A; Wright RC; Koziol A; Weiss A; Danahey K; Karrison TG; Edens CC; Ventura IB; Pettit NN; Patel B; Pisano J; Strek ME; Gajewski TF; Ratain MJ; Reid PD
    medRxiv; 2020 Jul; ():. PubMed ID: 32743594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.